This randomised, controlled study of children (5-15 years of age) with sickle cell anaemia studied the value of chronic RBC transfusion support (to maintain a target haemoglobin concentration greater than 9 g/dL and a target haemoglobin S less than 30% of total haemoglobin) compared with standard of care (observation group).
The primary endpoint, recurrence of infarct or haemorrhage as determined by neuroimaging, was reached in 6% and 14% of the patients, respectively, with a calculated incidence of 2.0 and 4.8 events per 100 years of risk (P = 0.04).
The implications of this study of transfusion therapy and long-term complications such as iron overload, when compared to other pharmalogic options such as hydroxyurea therapy, are discussed in an accompanying editorial.
– Lawrence Tim Goodnough
Discuss this article on the Nataonline forum